Health Condition 1: J459- Other and unspecified asthma Health Condition 2: null- Patients with Cough and/or wheeze and/or chronic dyspnoea with asthma.
Conditions
Interventions
Intervention1: Tablet Alerfix Total: Montelukast 10 MG+Levocetirizine 5 MG+Ambroxol 75 MG
Control Intervention1: Not Applicable: Not Applicable
Sponsors
Eris Life sciences Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Men or Women, between 18 to 80 years of age (both inclusive). 2. The patient experiencing Cough and/or wheeze and/or chronic dyspnoea or any other symptoms of NSRS with asthma 3. Patient indication and disease condition according to the â??INDICATION & USAGEâ?? as mentioned in the package insert available with Alerfix Total 4. Women of childbearing potential using an acceptable method of birth control. 5. Willing to give written informed consent for participation in the study and to comply with the study procedures
Exclusion criteria
Exclusion criteria: 1. Evidence of active liver disease or SGPT > 2.5 times upper limit of normal (ULN) 2. Evidence of renal impairment (Serum creatinine levels more than 2.0 mg /dl) 3. Pregnancy 4. Malignancy 5. Contraindication as mentioned in package insert 6. Patients with medical conditions that preclude the follow-up as defined in the protocol or otherwise limits participation in this study 7. Patients with known history of hypersensitivity to the study drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To explore the overall safety profile of Alerfix total, as measured by adverse events and Questionnaires, in patients with NSRS and asthma under conditions of routine medical practice.Timepoint: Not Applicable | — |
Secondary
| Measure | Time frame |
|---|---|
| Not ApplicableTimepoint: Not Applicable | — |
Countries
India
Contacts
Public ContactDr Hiren Gandhecha
Accutest Research Laboratories (I) Pvt Ltd
Outcome results
None listed